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We report the clinical features of, and the molecular study performed on, a Spanish family with essential tremor (ET), late onset
epilepsy and autosomal dominant hypokalemic periodic paralysis (hypoPP). The presence of hypoPP in this kindred suggested
an ion channel as a candidate gene for ET. Our study identified an Arg528His CACNL1A3 mutation in patients with hypoPP,
and excluded this mutation as the cause of tremor or epilepsy in this kindred.
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INTRODUCTION
Essential tremor (ET) is the most common move-
ment disorder and one of the most frequent neuro-
logical diseases1, 2. The importance of genetic factors
in ET pathogenesis is unanimously endorsed, due to
its frequent familial presentation and to the absence
of known environmental factors that could explain its
pathogenesis. To date, two loci have been identified by
linkage analysis in familial ET. The 3q13 locus was
reported in Iceland pedigrees3 and the 2p22-p25 locus
in one additional family4. These kindreds developed
an autosomal dominant form of ET, similar to the spo-
radic form. These results have not been replicated in
other pedigrees. Thus, despite the high prevalence of
this disease, available molecular genetic information
is scarce.
The factors that challenge the detection of genes un-
derlying ET include: incomplete and sometimes low
penetrance; the presence of atypical clinical features;
the existence of individuals in the pedigree affected by
sporadic, nongenetic causes of ET or phenocopies; and
the wide range of age of onset within families5.
These factors complicate the correct assignment of
affectation status to a given subject. Among different
kindreds, the existence of genetic heterogeneity, with
different genes leading to the same or similar pheno-
type, may obscure the detection of genetic linkage
when multiple families are summed in linkage studies.
These facts reinforce the use of a different method-
ology, such as candidate gene mutation analysis, to
evaluate ET pedigrees. In this approach, a particular
gene is hypothesized to be the locus for the disease, as
suggested for example by the cosegregation of the dis-
order under study with diseases of known genetic ori-
gin. The subsequent molecular genetic study will re-
veal if mutations in the candidate gene are present in
patients but not in normal controls6. In the present
work, genes related to ion channel diseases could be
considered as candidates for ET, given the good re-
sponse some ET patients have to calcium channel
blockers7, 8, or carbonic anhydrase inhibitors9, 10.
In this paper we report a Spanish family with as-
sociated essential tremor, late onset complex par-
tial seizures and hypokalemic periodic paralysis (hy-
poPP). These phenotypes could be explained by a
mutation in a single gene, e.g. a channelopathy. Fa-
milial hypoPP is due in most cases to mutations in
the CACNL1A3 gene, which encodes the α1 subunit
of the dihydropyridine receptor11, 12. Also, epileptic
seizures have been seen in other channelopathies13–16,
and there are forms of malignant hyperthermia, a dis-
order allelic to familial hypoPP17, linked to a locus
in the same chromosomal region as familial ET18.
We report the clinical features of this family and the
molecular study performed, to see if mutations in
CACNL1A3 were responsible for part or all of the
neurological phenotypes described.
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Fig. 1: Top: Kindred pedigree and phenotypes (familial hy-
poPP; ET and seizures). Below: 12% polyacrylamide gel
showing results of CACNL1A3 Arg528His mutation analysis
after digestion with the restriction enzyme BbvI. Patients I-1
and II-2 have an abnormal 77 bp band consistent with a het-
erozygote state for this mutation.
PATIENTS AND METHODS
Pedigree overview
The following data are from the kindred pedigree as
shown in Fig. 1. All individuals were directly evalu-
ated by at least one of us. Evaluation consisted of a
neurological history and physical examination to as-
certain affection status. We performed laboratory stud-
ies including plasma glucose, creatinine, hepatic func-
tion, erythrocyte sedimentation rate, creatine kinase
and thyroid status. The diagnosis of ET was based on
the presence of postural and kinetic tremor unilaterally
or bilaterally, anytime during the study period and on
the absence of any secondary causes. HypoPP was di-
agnosed when there was a typical history of transient
paralytic attacks. Hypokalemia during attacks was ob-
served but not considered a prerequisite. Age at on-
set of ET seizures or hypoPP was defined as the age
when an individual first complained of these neurolog-
ical symptoms. ET patients were videotaped according
to a standard protocol.
Molecular genetic study
Blood samples were collected after informed con-
sent. Total genomic DNA was isolated from blood
leukocytes by hypotonic lysis, followed by standard
phenol–chloroform extraction and ethanol precipita-
tion. Arg528His and Arg1239His mutations in the
CACNL1A3 gene, reported to exist in patients with
familial hypoPP, were studied by restriction enzyme
analysis, as previously described11, 12, 19. This proce-
dure is feasible in both cases because the Arg528His
mutation (CGC→CAC) causes the loss of a BbvI site,
while the Arg1239His mutation (CGT→CAT) creates
a new NlaIII restriction site. The procedure involved
PCR amplification, overnight enzyme digestion, 16%
polyacrylamide gel separation, and ethidium bromide
staining. Table 1 shows PCR primer pairs, annealing
temperatures and product lengths, along with restric-
tion enzymes and fragment lengths after digestion, for
normal and mutated DNA.
RESULTS AND CASE REPORTS
Pedigree overview
The kindred included four members in two consecu-
tive generations. The pedigree diagram in Fig. 1 shows
its pattern of inheritance and clinical manifestations,
along with restriction enzyme analysis results. Clini-
cal data are summarized in Table 2. Detailed case his-
tories are presented below. Two individuals in the first
generation had late onset seizures and ET, one with
hypoPP. In the second generation one individual had
hypoPP, while his sister was not affected, and neither
have developed seizures or tremor so far. The average
age at onset was 15 years old for hypoPP, 57 years
old for seizures and 68 years old for ET. The ET phe-
notype was identical to that seen in sporadic cases,
with asymmetric involvement initially, mild cogwheel
rigidity and neither akinesia nor postural instability.
Rate of progression was slow. Seizures were complex
partial or generalized. They were controlled with med-
ication (phenytoin or phenobarbitone) and tremor par-
tially responded to phenobarbitone. Dementia, pyra-
midal, cerebellar or autonomic disturbances were not
found. Laboratory investigations were normal in all
subjects. In spite of the small size of this pedigree,
hypoPP seemed to be transmitted with an autosomal
dominant pattern. It was not possible to assign a mode
of inheritance for ET and seizures as they were present
only in the first generation. However, in view of a pos-
itive history in one of the parents (not included, as de-
ceased), and to the absence of known consanguinity,
ET was also assumed to be an autosomal dominant.
Case reports
Case I-1.
This 80-year-old man presented attacks of periodic
paralysis caused by stress or exercise since his teens,
once every two to six months, until his fifties. Since
then he has had no more attacks. When 51 years old
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Table 1: Methods: Restriction enzyme assay.
Mutation Primers PCR annealing PCR product Enzyme Fragments length (bp)
Normal Mutated
Arg528His 5′-GGAGATCCTGCTGGTGGAGTCG-3′ 58 ◦C 77 bp BbvI 44, 33 77, –
5′-TCCTCAAGGAGGCGGATGCAG-3′
Arg1239His 5′-TCCAGCGCCTTCTTCCGCCT-3′ Touch down: 81 bp NlaIII 48, 33 48, 28, 5
5′-CAGGAGGGTTCGCACTCCTT-3′ 58 ◦C→ 50 ◦C
Table 2: Clinical manifestations.
Case # Age Sex Tremor Seizures Periodic paralysis CACLN1A3
(age at onset) (age at onset) (age at onset) mutation
I-1 80 M + (71) + (51) + (15) Arg528His
I-2 84 M + (74) + (64) — —
II-1 45 F — — — —
II-2 42 M — — + (16) Arg528His
M = male; F = female.
he began to have episodes of impaired awareness and
motor automatism that were treated with phenobarbi-
tone and phenytoin with good response. The medica-
tion was withdrawn 5 years later and the ictal episodes
recurred. At 71 years old he was first evaluated by us,
complaining of tremor in both upper limbs that inter-
fered with writing and eating. An EEG showed focal
left sharp wave discharges and a contrast-enhanced
cranial CT was normal. Tremor progressed slowly,
and, at the time of this report, 9 years later, it impaired
writing and daily activities. Propranolol ameliorated
the tremor but was discontinued because of associ-
ated adverse effects. Nimodipine did not improve his
tremor.
Case I-2.
This 84-year-old man had a history of complex partial
and generalized seizures, since he was 64. An EEG
showed bilateral temporal slow wave discharges, and
a cranial CT was normal. Since he was 74, he had mild
tremor in his left upper limb. Ten years later, seizures
were under good control with phenobarbitone, and
tremor did not impair his usual daily activities. ET
involved mainly the left forearm, in certain postures
at rest, but could also be seen while maintaining pos-
ture and in the finger-nose manoeuvre. At 79 years he
had two episodes of transient ataxia and diplopia, eval-
uated elsewhere as vertebrobasilar ischemic attacks.
Another cranial CT at that time was normal. He did
not have episodes of periodic paralysis.
Case II-1.
This 45-year-old woman had neither periodic paralysis
nor epileptic seizures or tremor.
Case II-2.
This 42-year-old man had periodic episodes of gener-
alized paralysis since 15 years of age, caused by stress
or exercise. Two of the episodes were observed in our
hospital and mild hypokalemia was recorded. There
was no evidence of epilepsy or tremor, at the time of
assessment.
Mutation analysis
NlaIII enzyme analysis showed normal results in all
the individuals, excluding an Arg1239His mutation.
On the other hand, after digestion with BbvI, cases I-1
and II-2 showed a 77 bp band along with the normal
33 and 44 bp bands, concordant to a heterozygote state
for the Arg528His mutation. Cases I-2 and II-1, did not
have this mutation. These results confirmed that famil-
ial hypoPP in this kindred was inherited in an autoso-
mal dominant fashion, due to this CACNL1A3 gene
mutation, with complete penetrance. The Arg528His
mutation did not segregate with the ET trait (Fig. 1).
DISCUSSION
Familial hypoPP is a disorder of muscle excitabil-
ity characterized by transient attacks of hypotonic
paralysis with variable severity and duration, and as-
sociated mild hypokalemia, that occur at intervals
of days to years20, 21. The main provocative factors
are rest after exercise and carbohydrate-rich meals.
The most frequent age of onset is within the sec-
ond decade of life, and it usually remits at older
ages. It is an autosomal dominant disease with in-
complete penetrance19. Late in the course of the dis-
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ease these patients may develop a vacuolar myopathy,
not related to the frequency or intensity of episodes.
It is a voltage-gated muscle calcium channel disor-
der. Initial genetic studies linked this disease to a
locus in chromosome 1q22; later, it was discovered
to correspond to mutations in the CACNL1A3 gene
which encodes the α1 subunit of the skeletal mus-
cle L-type calcium channel, named the dyhidropyri-
dine receptor11. Three point mutations have been iden-
tified in this gene, to date: Arg528His, Arg1239His
and Arg1239Gly. The first one is the most usual,
while the last one is very uncommon11, 12. Never-
theless these mutations do not explain all familial hy-
poPP cases.
There are no reports of other neurological disorders
in familial hypoPP. However, the family we report pre-
sented hypoPP, along with late-onset seizures and ET,
only manifest in the first generation studied to date.
The late-onset age of tremor and seizures in this kin-
dred could explain the absence of these manifestations
in the second generation individuals. Also, as familial
hypoPP may have an incomplete penetrance, case I-2
could be an asymptomatic carrier of this trait. More-
over, as referred above, both ET and hypoPP seemed
to be transmitted with an autosomal dominant pattern.
All these facts suggest that a mutation in a single gene
with variable penetrance could be the cause of these
phenotypes.
Both clinical and genetic factors point to an ion
channel disorder in the family presented: on clinical
grounds, this interpretation agrees with several reports
of a positive response in ET to calcium-receptor an-
tagonists, which bind to the dyhidropyridine recep-
tor, an L-type voltage-gated receptor7, 8. Genetic jus-
tification for our hypothesis includes evidence that
relate epilepsy or tremor to channelopathies. Spe-
cific epileptic syndromes are associated with muta-
tions in the gene for the β1 subunit of voltage-gated
sodium channel SCN1B13, and in the potassium chan-
nel genes KCNQ2 and KCNQ314, 15. In addition, a
disturbance in the ATP-sensitive potassium channel
system has been found in patients with familial hy-
poPP20. Also, individuals with mutations in the hu-
man voltage-gated potassium channel Kv1.1, respon-
sible for episodic ataxia type 1, sometimes have gener-
alized or secondarily generalized seizures, during the
course of the disease16, and a mouse knockout for
Kv1.1 has a lethal epilepsy phenotype23. Moreover,
CACNA1A gene mutations, responsible for episodic
ataxia type 2 and migraine in humans, cause seizures
in mice24. Tremor mimicking essential tremor can be
seen in both episodic ataxia type 1 and type 216, 25.
Finally, one of the loci associated with familial ET is
in the same chromosomal region as a form of malig-
nant hyperthermia (3q13)3, 17. This disease is usually
caused by alterations in the ryanodine receptor, but
there is a form, allelic with hypoPP18, in which an al-
teration in the dyhidropyridine receptor causes an ab-
normal interaction with the ryanodine receptor in the
electrical–mechanical coupling of muscle contraction.
Taking all above considerations together, genes that
could link ET and/or epileptic seizures to familial
hypoPP in the kindred presented include those cod-
ing the L-type calcium channel. Among these, the
CACNL1A3 gene is a good candidate, since it is re-
sponsible for most cases of familial hypoPP but, as
stated above, mutations have not been linked so far to
systemic diseases. We therefore performed a molecu-
lar analysis of CACNL1A3 mutations that could ac-
count for hypoPP in this family. At the same time, the
molecular analysis would help to confirm or exclude
the hypothesis of a single monogenic disease respon-
sible for the phenotypes in this kindred.
The molecular analysis of CACNL1A3 gene muta-
tions performed by us showed that case I-2, with ET
and late onset seizures, did not have the Arg528His
mutation that segregated with the hypoPP trait. The
coexistence of seizures and ET of similar character-
istics and age of onset in cases I-1 and I-2 makes it
very unlikely that there is a phenocopy in case I-2.
This family thus presented hypoPP caused by an
Arg528His mutation in the CACNL1A3 gene in two
individuals, and unlinked familial ET and late onset
seizures in others. Moreover, calcium channel antag-
onists did not relieve the tremor. In conclusion, these
results do not support an L-type calcium channel as a
candidate gene for ET in the family presented.
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